title: Effects of voriconazole co-administration on oxycodone-induced adverse events: a case in the retrospective survey.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Watanabe
authors.forename: Masato
authors.initials: M
authors.lastname: Homma
authors.forename: Kenji
authors.initials: K
authors.lastname: Momo
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Okoshi
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Wada
authors.forename: Akira
authors.initials: A
authors.lastname: Hara
authors.forename: Shigeru
authors.initials: S
authors.lastname: Chiba
authors.forename: Yukinao
authors.initials: Y
authors.lastname: Kohda
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000009:adverse effects*; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000150:complications / Q000188:drug therapy*; D002051:Burkitt Lymphoma / Q000150:complications / Q000503:physiopathology*; D059350:Chronic Pain / Q000188:drug therapy* / Q000209:etiology; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000150:complications / Q000188:drug therapy; D010098:Oxycodone / Q000009:adverse effects*; D011743:Pyrimidines / Q000627:therapeutic use*; D017450:Receptors, Opioid, mu / Q000819:agonists; D012189:Retrospective Studies; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
chemical_list: D000701:Analgesics, Opioid; D000935:Antifungal Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D004791:Enzyme Inhibitors; D011743:Pyrimidines; D017450:Receptors, Opioid, mu; D014230:Triazoles; D010098:Oxycodone; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D065819:Voriconazole